The United States smart pills market is projected to grow from US$1.53 billion in 2024 to US$4.13 billion by 2033, reflecting a compound annual growth rate (CAGR) of 11.66% from 2025 to 2033, according to the newly released United States Smart Pills Market — Drug Delivery Innovation & Forecast 2025-2033 report from ResearchAndMarkets.com.
What Are Smart Pills?
Also known as digital pills or ingestible sensors, smart pills are advanced medications embedded with microscopic electronic components such as transmitters, microchips, and sensors. After ingestion, they interact with biological fluids and send real-time health data to external devices. This technology enables healthcare providers and researchers to monitor physiological responses, track medication adherence, and gather health indicators to improve treatment plans, support personalized medicine, and enhance clinical trials.
Key Growth Drivers
1. Rising demand for minimally invasive diagnostics
Smart pills are gaining adoption for diagnosing gastrointestinal and colon-related conditions without invasive procedures.
2. Increasing prevalence of chronic diseases
Conditions such as kidney disease, diabetes, and gastrointestinal disorders are creating demand for advanced monitoring tools. As of February 2022, an estimated 37 million Americans have kidney disease, with 92,000 awaiting transplants. In 2022, the American Cancer Society projected 79,000 new cases of kidney cancer.
3. Technological advancements
Progress in wireless connectivity, sensor integration, and miniaturization is improving device reliability and expanding clinical uses.
4. Aging population
Older adults face a higher risk of chronic illnesses, increasing the need for ongoing health monitoring.
5. Integration with telemedicine
Smart pills complement virtual care by providing remote monitoring capabilities, a trend accelerated by the COVID-19 pandemic.
6. Increased R&D investment
Pharmaceutical and medical device companies are investing heavily to expand applications and improve device performance.
Challenges Facing the Market
High cost of technology
Advanced components and manufacturing processes make smart pills expensive, limiting accessibility for some patients and healthcare providers.
Regulatory hurdles
Lengthy approval processes from the FDA and other regulatory agencies can slow product launches. Evolving technology often raises new regulatory questions that existing frameworks do not fully address.
Recent Industry Developments
- January 2025: The FDA approved CapsoVision’s CapsoCam Plus for pediatric patients aged two and older, offering a non-invasive diagnostic option that avoids the discomfort of traditional endoscopy.
- January 2024: The FDA expanded indications for AnX Robotics’ NaviCam Small Bowel Video Capsule Endoscopy for both adults and children as young as two, and approved ProScan, an AI-assisted reading tool for video capsule endoscopy.
Leading Companies in the U.S. Smart Pills Market
- Check-Cap Ltd.
- General Electric Company
- Fujifilm
- Koninklijke Philips N.V.
- Medtronic plc
- Olympus Corporation
- Novartis AG
- Otsuka Holdings Co., Ltd.
For more information about this report, visit https://www.researchandmarkets.com/r/9qk5fh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.